Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) EBIT: 2020-2025

Historic EBIT for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to -$3.3 million.

  • GeneDx Holdings' EBIT rose 58.21% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 117.28%. This contributed to the annual value of -$23.2 million for FY2024, which is 87.15% up from last year.
  • As of Q3 2025, GeneDx Holdings' EBIT stood at -$3.3 million, which was down 136.28% from $9.0 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year EBIT high stood at $9.0 million for Q2 2025, and its period low was -$324.9 million during Q4 2022.
  • In the last 3 years, GeneDx Holdings' EBIT had a median value of -$10.6 million in 2024 and averaged -$18.4 million.
  • As far as peak fluctuations go, GeneDx Holdings' EBIT slumped by 257.88% in 2022, and later soared by 184.70% in 2025.
  • Over the past 5 years, GeneDx Holdings' EBIT (Quarterly) stood at -$115.8 million in 2021, then plummeted by 180.60% to -$324.9 million in 2022, then skyrocketed by 92.11% to -$25.6 million in 2023, then skyrocketed by 134.34% to $8.8 million in 2024, then skyrocketed by 58.21% to -$3.3 million in 2025.
  • Its last three reported values are -$3.3 million in Q3 2025, $9.0 million for Q2 2025, and -$4.6 million during Q1 2025.